Probiotics and chronic kidney disease

Kidney International

Volumn 88, Issue 5, 2015, Pages 958-966

  Koppe, Laetitia ^a   Mafra, Denise ^b   Fouque, Denis ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Chronic kidney disease; Gut; Inflammation; Microbiota; Probiotic

Indexed keywords

PROBIOTIC AGENT; INDOLE DERIVATIVE; PHENOL DERIVATIVE; TOXIN;

ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DYSBIOSIS; HEALTH CARE QUALITY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INTESTINE FLORA; KIDNEY FUNCTION; NEPHRITIS; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; TOXIN SYNTHESIS; COMPLICATION; GASTROINTESTINAL TRACT; INFLAMMATION; METABOLISM; MICROBIOLOGY; MICROFLORA; RENAL INSUFFICIENCY, CHRONIC; UREMIA;

DYSBIOSIS; GASTROINTESTINAL TRACT; HUMANS; INDOLES; INFLAMMATION; MICROBIOTA; PHENOLS; PROBIOTICS; RENAL INSUFFICIENCY, CHRONIC; TOXINS, BIOLOGICAL; UREMIA;

EID: 84947617491     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.255     Document Type: Short Survey

References (58)

1. Evenepoel P, Meijers BK, Bammens BR et al. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009; 114: S12-S19.
2. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 2014; 25: 657-670.
3. Power SE, O'Toole PW, Stanton C et al. Intestinal microbiota, diet and health. Br J Nutr 2014; 111: 387-402.
4. Vaziri ND, Wong J, Pahl M et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 2012; 83: 308-315.
5. Food and Agriculture Organsization. Guidelines for the Evaluation of Probiotics in Food. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. Food and Agriculture Organization: London, 2002.
6. Ebel B, Lemetais G, Beney L et al. Impact of probiotics on risk factors for cardiovascular diseases. A review. Crit Rev Food Sci Nutr 2014; 54: 175-189.
7. Vaziri ND, Yuan J, Rahimi A et al. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant 2012; 27: 2686-2693.
8. Vaziri ND, Zhao Y-Y, Pahl MV. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant 2015 (doi:10. 1093/ndt/gfv095).
9. Anders H-J, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013; 83: 1010-1016.
10. Koppe L, Pelletier CC, Alix PM et al. Insulin resistance in chronic kidney disease: new lessons from experimental models. Nephrol Dial Transplant 2014; 29: 1666-1674.
11. Khan MT, Nieuwdorp M, Bäckhed F. Microbial modulation of insulin sensitivity. Cell Metab 2014; 20: 753-760.
12. Mafra D, Lobo JC, Barros AF et al. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol 2014; 9: 399-410.
13. Hill C, Guarner F, Reid G et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506-514.
14. Johnson-Henry KC, Hagen KE, Gordonpour M et al. Surface-layer protein extracts from Lactobacillus helveticus inhibit enterohaemorrhagic Escherichia coli O157:H7 adhesion to epithelial cells. Cell Microbiol 2007; 9: 356-367.
15. Mack DR, Ahrne S, Hyde L, Wei S et al. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003; 52: 827-833.
16. Yan F, Cao H, Cover TL et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007; 132: 562-575.
17. Seth A, Yan F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC-and MAP kinasedependent mechanism. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1060-G1069.
18. Mennigen R, Nolte K, Rijcken E et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1140-G1149.
19. Fanning S, Hall LJ, Cronin M et al. Bifidobacterial surfaceexopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc Natl Acad Sci USA 2012; 109: 2108-2113.
20. Keddis MT, Khanna S, Noheria A et al. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc 2012; 87: 1046-1053.
21. Fayol-Messaoudi D, Berger CN, Coconnier-Polter M-H et al. pH-, Lactic acid-, and non-lactic acid-dependent activities of probiotic Lactobacilli against Salmonella enterica Serovar Typhimurium. Appl Environ Microbiol 2005; 71: 6008-6013.
22. Corr SC, Li Y, Riedel CU et al. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 2007; 104: 7617-7621.
23. Schlee M, Harder J, Köten B et al. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 2008; 151: 528-535.
24. Medellin-Peña MJ, Wang H, Johnson R et al. Probiotics affect virulencerelated gene expression in Escherichia coli O157:H7. Appl Environ Microbiol 2007; 73: 4259-4267.
25. Linden SK, Sutton P, Karlsson NG et al. Mucins in the mucosal barrier to infection. Mucosal Immunol 2008; 1: 183-197.
26. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008; 8: 411-420.
27. Dalmasso G, Cottrez F, Imbert V et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006; 131: 1812-1825.
28. O'Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551.
29. Delzenne NM, Neyrinck AM, Bäckhed F et al. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 2011; 7: 639-646.
30. Sayin SI, Wahlström A, Felin J et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17: 225-235.
31. Begley M, Hill C, Gahan CGM. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 2006; 72: 1729-1738.
32. Everard A, Belzer C, Geurts L et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013; 110: 9066-9071.
33. Hida M, Aiba Y, Sawamura S et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996; 74: 349-355.
34. Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis 2003; 41: S142-S145.
35. Nakabayashi I, Nakamura M, Kawakami K et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant 2010; 26: 1094-1098.
36. Simenhoff ML, Dunn SR, Zollner GP et al. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab 1996; 22: 92-96.
37. Rossi M, Johnson DW, Morrison M et al. SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. BMC Nephrol 2014; 15: 106.
38. Gupta J, Mitra N, Kanetsky PA et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 2012; 7: 1938-1946.
39. Andrade-Oliveira V, Amano MT, Correa-Costa M et al. gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 2015; 26: 1877-1888.
40. Wang I-K, Wu YY, Yang YF et al. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benef Microbes 2015; 6: 423-430.
41. Natarajan R, Pechenyak B, Vyas U et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. BioMed Res Int 2014; 2014: 568571.
42. Viramontes-Hörner D, Márquez-Sandoval F, Martín-del-Campo F et al. Effect of a Symbiotic Gel (Lactobacillus acidophilus+Bifidobacterium lactis +Inulin) on presence and severity of gastrointestinal symptoms in hemodialysis patients. J Ren Nutr 2015; 25: 284-291.
43. Ranganathan N, Patel BG, Ranganathan P et al. In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO J 2006; 52: 70-79.
44. Prakash S, Chang TM. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat Med 1996; 2: 883-887.
45. Ranganathan N, Ranganathan P, Friedman EA et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 2010; 27: 634-647.
46. Miranda Alatriste PV, Urbina Arronte R, Gómez Espinosa CO, Espinosa Cuevas, M. de los Á. Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp 2014; 29: 582-590.
47. Pavan M. Influence of prebiotic and probiotic supplementation on the progression of chronic kidney disease. Minerva Urol Nefrol 2014.
48. Goldfarb DS, Modersitzki F, Asplin JR. A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol 2007; 2: 745-749.
49. Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 2013; 37: 1-6.
50. Hempel S, Newberry S, Ruelaz A et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess 2011; 200: 1-645.
51. Del Piano M, Strozzi P, Barba M et al. In vitro sensitivity of probiotics to human pancreatic juice. J Clin Gastroenterol 2008; 42(Suppl 3, Pt 2): S170-S173.
52. Cruz-Mora J, Martínez-Hernández NE, Martín del Campo-López F et al. Effects of a symbiotic on gut microbiota in mexican patients with endstage renal disease. J Ren Nutr 2014; 24: 330-335.
53. Buffie CG, Bucci V, Stein RR et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015; 517: 205-208.
54. Ranganathan N, Patel B, Ranganathan P et al. Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats. ScientificWorldJournal 2005; 5: 652-660.
55. Guida B, Germanò R, Trio R et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutr Metab Cardiovasc Dis 2014; 24: 1043-1049.
56. Ranganathan N, Friedman EA, Tam P et al. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr Med Res Opin 2009; 25: 1919-1930.
57. Taki K, Takayama F, Niwa T. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr 2005; 15: 77-80.
58. Ando Y, Miyata Y, Tanba K et al. [Effect of oral intake of an enteric capsule preparation containing Bifidobacterium longum on the progression of chronic renal failure]. Nihon Jinzo Gakkai Shi 2003; 45: 759-764.